Opinion|Videos|October 31, 2024
Maneuvering Through Different Treatment Options for Ovarian Cancer
With Martina Murphy, MD, the Oncology Brothers discuss maneuvering through different treatment options for ovarian cancer, emphasizing the need for personalized approaches to optimize patient care and outcomes.
Advertisement
Episodes in this series
Advertisement
Related to this article
In the phase 3 Alliance A071801 trial, postoperative fractionated SRS improved surgical bed control vs single-fraction SRS without added toxicity.
In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.
William A. Hall, MD, reviews resection rates, surgical complications, and SBRT target volumes from the SOFT Preop study in pancreatic cancer.
Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.
William A. Hall, MD, explains how fewer visits, no concurrent chemotherapy, and adaptive MRI guidance may have preserved quality of life with SBRT.
“We are not just treating the cancer; we are treating the patient,” said Marcio A. Fagundes, MD.
Poster presentations at IMS 2026 highlighted the use of venetoclax, daratumumab, and different combination regimens across various treatment settings.
Patient enrollment of the phase 3 IDeate-Lung02 trial assessing I-DXd vs chemotherapy in relapsed ES-SCLC will continue following the withdrawal.
Advertisement
Advertisement
Trending on CancerNetwork
1
Where Does Intensity-Modulated Proton Therapy Fit in Prostate Cancer?
2
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
3
FDA Discussion Prompts Voluntary Withdrawal of BLA for I-DXd in ES-SCLC
4
IMS 2026: Key Updates Across The Multiple Myeloma Paradigm
5